
Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
<a href="https://news.google.com/rss/articles/CBMiwAJBVV95cUxNYzBtX0xINkRSQ2tKaXBqZkEwR3JtTkdJNWQxQnJSMTEtd2taTk1NR2NUUVd0RTdpR1N2aEViaXRNLXZMc19JYWhnNzZFY1VmaFVLZFhTZC1PXzlvQzdsZmt5UHV4OThwZXRKa3VLblVWVUFpUEg2eDcwUnpqYk10ZVBGcE9GY3BUcW9Rc0xvcjY3V0tUSThKTzNZZkxlZG8zWFFvdUpfUzFKWnZBdVNfcjY4aDBtYVdJVHVsSXQwNk10VXZjamZwRWFPbmx0WlFpNUpUMlJPTXhXUy12eC1FYkZqa1BEOXQtbmZLZ1VzVFhodkprUWI4Qm9HV1dpNkQwWHdZWmZaTjBocHlzQW9LMEdwOE5uRWV0YmItVzlsYmNaYkJWZXNTN1kxMFptUVBPdUFvcy1IVVVvem9ORWhlNQ?oc=5" target="_blank">Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension</a>&nbsp;&nbsp;<font color="#6f6f6f">Insmed Incorporated Investor Relations</font>
